Along with Pfizer’s vaccine we have many vaccine candidates that seem to be on the cusp of approval. This no doubts complicates the decision that policymakers have to make. How would you like policymakers to think through and make that comparison? Melisa Idris and Sharaad Kuttan speak to Sanjeev Krishna, Professor of Molecular Parasittology and Medicine, Institute of Infection and Immunity in London.